Boston Biochem, Inc. is the leading global producer of ubiquitin-related research products. Since 1997, it has been our mission to provide ubiquitin proteasome pathway (UPP) researchers with innovative tools that facilitate and accelerate drug discovery efforts. Boston Biochem specializes in several related product lines for ubiquitin and ubiquitin-like (UBL) proteins (e.g. Apg8, FAT10, ISG15, NEDD8, SUMO, UFM1) and associated enzymes, substrates, inhibitors and kits.
In 2011, Boston Biochem was acquired by TECHNE Corporation’s R&D Systems, a leading supplier of cell biology reagents with more than 20 years of experience and a unique product manufacturing model that ensures strict quality control and the highest level of consistency and performance in their products.
With R&D System’s expertise in sales, distribution and logistics in place, Boston Biochem is now exclusively focused on new product development. Extensive expertise in protein purification, characterization, modification and assay development as well as a close relationship with the UPP research community allows us to continue to offer the most comprehensive product range available.
Our acquisition also gives us the opportunity to co-develop complementary antibodies, ELISAs and kits from R&D Systems and complementary inhibitors and substrates from Tocris Bioscience. All Boston Biochem specialized tools continue to be developed, produced, and characterized in-house with a commitment to affordability and excellence.
In 2014, Techne becomes Bio-Techne, joining Boston Biochem with the other core brands of R&D Systems and Tocris to provide researchers with a broad array of products and services. The same ubiquitin expertise and quality that you have come to expect from us will be more readily available as we become Boston Biochem - a Bio-Techne Brand.